Advertisement

von Willebrand Disease

  • Akbar Dorgalaleh
  • Shadi Tabibian
  • Yavar Shiravand
  • Emmanuel J. Favaloro
Chapter

Abstract

von Willebrand disease (VWD) is the most common congenital bleeding disorder with an estimated incidence of 1% in the general population. The disorder is classified into three main types: type 1 and type 3 as quantitative deficiency and type 2 as qualitative defects. The bleeding tendency is highly variable in VWD, ranging from an asymptomatic condition, mainly in type 1 VWD, to severe life-threatening hemorrhage, most notably in type 3 VWD. Diagnosis of the disorder is sophisticated and requires advanced laboratory testing and precise clinical assessment. Bleeding symptoms, decreased VWF level and/or activity, and the pattern of inheritance are three main criteria for appropriate and timely diagnosis of VWD. Although on-demand therapy is the mainstay of treatment in VWD, long-term prophylaxis is recommended for those with recurrent and severe hemorrhages. Different therapeutic choices are available in VWD including VWF/FVIII concentrates, recombinant VWF, desmopressin, and, in some locations, fresh frozen plasma (FFP). With timely diagnosis and appropriate management of the VWD, the burden of the disorder can be alleviated or even eliminated.

Keywords

von Willebrand disease Congenital bleeding disorders Diagnosis Management 

References

  1. 1.
    Robertson J, Lillicrap D, James PD. von Willebrand disease. Pediatr Clin N Am. 2008;55(2):377–92.CrossRefGoogle Scholar
  2. 2.
    James PD, Goodeve AC. von Willebrand disease. Genet Med. 2011;13(5):365–76.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Sadler J, Budde U, Eikenboom J, Favaloro E, Hill F, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103–14.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Federici A. Clinical diagnosis of von Willebrand disease. Haemophilia. 2004;10(s4):169–76.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Federici AB. Diagnosis of inherited von Willebrand disease: a clinical perspective. Semin Thromb Hemost. 2006;124:S1.Google Scholar
  6. 6.
    Favaloro EJ, Pasalic L, Curnow J. Laboratory tests used to help diagnose von Willebrand disease: an update. Pathology. 2016;48(4):303–18.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Sadler J, Mannucci P, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84(2):160–74.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood. 2002;99(2):450–6.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Lenting PJ, Christophe OD, Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015;125(13):2019–28.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Ginsburg D, Handin RI, Bonthron DT, Donlon TA, Bruns GA, Latt SA, et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science. 1985;228:1401–7.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Mancuso D, Tuley E, Westfield L, Worrall N, Shelton-Inloes B, Sorace J, et al. Structure of the gene for human von Willebrand factor. J Biol Chem. 1989;264(33):19514–27.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Collins CJ, Underdahl JP, Levene RB, Ravera CP, Morin MJ, Dombalagian MJ, et al. Molecular cloning of the human gene for von Willebrand factor and identification of the transcription initiation site. Proc Natl Acad Sci. 1987;84(13):4393–7.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Federici AB, Lee CA, Berntorp EE, Lillicrap D, Montgomery RR. Von Willebrand disease: basic and clinical aspects. Hoboken: Wiley; 2011.CrossRefGoogle Scholar
  14. 14.
    Zhou Y-F, Eng ET, Zhu J, Lu C, Walz T, Springer TA. Sequence and structure relationships within von Willebrand factor. Blood. 2012;120(2):449–58.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Shapiro S, Nowak A, Wooding C, Birdsey G, Laffan M, McKinnon T. The von Willebrand factor predicted unpaired cysteines are essential for secretion. J Thromb Haemost. 2014;12(2):246–54.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Tjernberg P, Vos HL, Castaman G, Bertina RM, Eikenboom JC. Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. J Thromb Haemost. 2004;2(2):257–65.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Hommais A, Stépanian A, Fressinaud E, Mazurier C, Pouymayou K, Meyer D, et al. Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease. Thromb Haemost. 2006;95(5):776–81.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Voorberg J, Fontijn R, Van Mourik J, Pannekoek H. Domains involved in multimer assembly of von Willebrand factor (vWF): multimerization is independent of dimerization. EMBO J. 1990;9(3):797.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112(1):11–8.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Zanardelli S, Crawley JT, Chion CKCK, Lam JK, Preston RJ, Lane DA. ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem. 2006;281(3):1555–63.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Zanardelli S, Chion AC, Groot E, Lenting PJ, McKinnon TA, Laffan MA, et al. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood. 2009;114(13):2819–28.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Samor B, Michalski JC, Debray H, Mazurier C, Goudemand M, Halbeek H, et al. Primary structure of a new tetraantennary glycan of the N-acetyllactosaminic type isolated from human factor VIII/von Willebrand factor. FEBS J. 1986;158(2):295–8.Google Scholar
  23. 23.
    Canis K, McKinnon TA, Nowak A, Haslam SM, Panico M, Morris HR, et al. Mapping the N-glycome of human von Willebrand factor. Biochem J. 2012;447(2):217–28.PubMedCrossRefGoogle Scholar
  24. 24.
    Carew JA, Browning PJ, Lynch DC. Sulfation of von Willebrand factor. Blood. 1990;76(12):2530–9.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Haberichter SL, Merricks EP, Fahs SA, Christopherson PA, Nichols TC, Montgomery RR. Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells. Blood. 2005;105(1):145–52.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell. 1986;46(2):185–90.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol. 2001;14(2):257–79.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Nightingale T, Cutler D. The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story. J Thromb Haemost. 2013;11(s1):192–201.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Skipwith CG, Cao W, Zheng XL. Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress. J Biol Chem. 2010;285(37):28596–603.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TA. major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem. 1987;262(18):8443–6.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Bahou W, Ginsburg D, Sikkink R, Litwiller R, Fass D. A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide. J Clin Investig. 1989;84(1):56.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Ginsburg D, Bockenstedt P, Allen E, Fox D, Foster P, Ruggeri Z, et al. Fine mapping of monoclonal antibody epitopes on human von Willebrand factor using a recombinant peptide library. Thromb Haemost. 1992;67(1):166–71.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Ruggeri ZM, Mendolicchio G. Interaction of von Willebrand factor with platelets and the vessel wall. Hämostaseologie. 2015;35(3):211–24.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Roth GJ, Titani K, Hoyer LW, Hickey MJ. Localization of binding sites within human von Willebrand factor for monomeric type III collagen. Biochemistry. 1986;25(26):8357–61.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Cruz MA, Yuan H, Lee JR, Wise RJ, Handin RI. Interaction of the von Willebrand factor (vWF) with collagen Localization of the primary collagen-binding site by analysis of recombinant vWF a domain polypeptides. J Biol Chem. 1995;270(18):10822–7.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Pareti FI, Niiya K, McPherson J, Ruggeri Z. Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. J Biol Chem. 1987;262(28):13835–41.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Hoylaerts MF, Yamamoto H, Nuyts K, Vreys I, Deckmyn H, Vermylen J. von Willebrand factor binds to native collagen VI primarily via its A1 domain. Biochem J. 1997;324(1):185–91.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67(1):395–424.PubMedCrossRefGoogle Scholar
  39. 39.
    Fujimura Y, Titani K, Holland L, Russell S, Roberts J, Elder J, et al. von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem. 1986;261(1):381–5.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Scott J, Montgomery R, Retzinger G. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem. 1991;266(13):8149–55.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Wohner N, Legendre P, Casari C, Christophe O, Lenting P, Denis C. Shear stress-independent binding of von Willebrand factor-type 2B mutants p. R1306Q & p. V1316M to LRP1 explains their increased clearance. J Thromb Haemost. 2015;13(5):815–20.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Andrews RK, López J, Berndt MC. Molecular mechanisms of platelet adhesion and activation. Int J Biochem Cell Biol. 1997;29(1):91–105.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Shelton-Inloes BB, Titani K, Sadler JE. cDNA sequences for human von Willebrand factor reveal five types of repeated domains and five possible protein sequence polymorphisms. Biochemistry. 1986;25(11):3164–71.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Mohri H, Fujimura Y, Shima M, Yoshioka A, Houghten R, Ruggeri Z, et al. Structure of the von Willebrand factor domain interacting with glycoprotein Ib. J Biol Chem. 1988;263(34):17901–4.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, et al. Amino acid sequence of human von Willebrand factor. Biochemistry. 1986;25(11):3171–84.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Berndt MC, Ward CM, Booth WJ, Castaldi PA, Mazurov AV, Andrews RK. Identification of aspartic acid 514 through glutamic acid 542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetin. Biochemistry. 1992;31(45):11144–51.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Knott HM, Berndt MC, Kralicek AV, O'Donoghue SI, King GF. Determination of the solution structure of a platelet-adhesion peptide of von Willebrand factor. Biochemistry. 1992;31(45):11152–8.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie GA, Ginsberg MH. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci. 1985;82(23):8057–61.PubMedCrossRefGoogle Scholar
  49. 49.
    Fressinaud E, Baruch D, Girma J-P, Sakariassen KS, Baumgartner HR, von Meyer D. Willebrand factor-mediated platelet adhesion to collagen involves platelet membrane glycoprotein IIb-IIIa as well as glycoprotein Ib. Transl Res. 1988;112(1):58–67.Google Scholar
  50. 50.
    Aoki T, Tomiyama Y, Honda S, Mihara K, Yamanaka T, Okubo M, et al. Association of the antagonism of von Willebrand factor but not fibrinogen by platelet αIIbβ3 antagonists with prolongation of bleeding time. J Thromb Haemost. 2005;3(10):2307–14.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    von Ginsburg D. Willebrand disease. In: Williams hematology. 6th ed. Philadelphia: McGraw-Hill; 2001. p. 1813–28.Google Scholar
  52. 52.
    Eikenboom JC. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol. 2001;14(2):365–79.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood. 2007;109(1):112–21.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Laffan M, Brown S, Collins PW, Cumming A, Hill F, Keeling D, et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors’ Organization. Haemophilia. 2004;10(3):199–217.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Peake I, Goodeve A. Type 1 von Willebrand disease. J Thromb Haemost. 2007;5(s1):7–11.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Laffan MA, Lester W, O’donnell JS, Will A, Tait RC, Goodeve A, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014;167(4):453–65.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69(6):1691–5.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Quiroga T, Goycoolea M, Belmont S, Panes O, Aranda E, Zuniga P, et al. Quantitative impact of using different criteria for the laboratory diagnosis of type 1 von Willebrand disease. J Thromb Haemost. 2014;12(8):1238–43.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood. 2003;101(6):2089–93.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol. 2001;14(2):337–47.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Sutherland JJ, O’Brien LA, Lillicrap D, Weaver DF. Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations. J Mol Model. 2004;10(4):259–70.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Woods AI, Kempfer AC, Paiva J, Sanchez-Luceros A, Bermejo E, Chuit R, et al. Phenotypic parameters in genotypically selected type 2B von Willebrand disease patients: a large, single-center experience including a new novel mutation. Semin Thromb Hemost. 2017;43:92–100.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Leebeek FW, Eikenboom JC. Von Willebrand’s disease. N Engl J Med. 2016;375(21):2067–80.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Patzke J, Favaloro EJ. Laboratory testing for von Willebrand factor activity by glycoprotein Ib binding assays (VWF:GPIb). Methods Mol Biol. 1646;2017:453–60.Google Scholar
  65. 65.
    Perez Botero J, Pruthi RK, Nichols WL, Ashrani AA, Patnaik MM. von Willebrand disease type1/type 2N compound heterozygotes: diagnostic and management challenges. Br J Haematol. 2017;176(6):994–7.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Lak M, Peyvandi F, Mannucci P. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol. 2000;111(4):1236–9.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Federici A, Castaman G, Mannucci P. Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia. 2002;8(5):607–21.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Federici AB, Bucciarelli P, Castaman G, Mazzucconi MG, Morfini M, Rocino A, et al. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood. 2014;123(26):4037–44.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Rodeghiero F, Tosetto A, Abshire T, Arnold D, Coller B, James P, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063–5.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Makris M. Gastrointestinal bleeding in von Willebrand disease. Thromb Res. 2006;118:S13–S7.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici A, Batlle J, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4(4):766–73.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Hyatt SA, Wang W, Kerlin BA, O'brien SH. Applying diagnostic criteria for type 1 von Willebrand disease to a pediatric population. Pediatr Blood cancer. 2009;52(1):102–7.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Castaman G, Tosetto A, Cappelletti A. Clinical presentation of type 1 von Willebrand disease in obligatory carriers: final results from a collaborative, international, multicentre study. J Thromb Haemost. 2003; Suppl. 1: Abstract OC078.Google Scholar
  74. 74.
    Castaman G, Federici A, Tosetto A, La Marca S, Stufano F, Mannucci P, et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost. 2012;10(4):632–8.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Favaloro EJ. Diagnosing von Willebrand disease: a short history of laboratory milestones and innovations, plus current status, challenges, and solutions. Semin Thromb Hemost. 2014;40(5):551–70.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Just S. Laboratory testing for von Willebrand disease: the past, present, and future state of play for von Willebrand factor assays that measure platelet binding activity, with or without Ristocetin. Semin Thromb Hemost. 2017;43(1):75–91.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Bodo I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(7):1345–50.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Favaloro EJ, Bonar RA, Meiring M, Duncan E, Mohammed S, Sioufi J, et al. Evaluating errors in the laboratory identification of von Willebrand disease in the real world. Thromb Res. 2014;134(2):393–403.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Favaloro E, Bonar R, Mohammed S, Arbelaez A, Niemann J, Freney R, et al. Type 2M von Willebrand disease–more often misidentified than correctly identified. Haemophilia. 2016;22(3):e145–55.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Favaloro EJ, Bonar R, Kershaw G, Sioufi J, Baker R, Hertzberg M, et al. Reducing errors in identification of von Willebrand disease: the experience of the Royal College of Pathologists of Australasia Quality Assurance Program. Semin thromb hemost. 2006;32:505–13.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Favaloro EJ, Mohammed S. Towards improved diagnosis of von Willebrand disease: comparative evaluations of several automated von Willebrand factor antigen and activity assays. Thromb Res. 2014;134(6):1292–300.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Favaloro EJ, Mohammed S. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. Thromb Res. 2016;141:202–11.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Blanchette VS, Srivastava A. Definitions in hemophilia: resolved and unresolved issues. Semin Thromb Hemost. 2015.  https://doi.org/10.1055/s-0035-1564800
  84. 84.
    Favaloro E. Genetic testing for von Willebrand disease: the case against. J Thromb Haemost. 2010;8(1):6–12.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Lillicrap D. The molecular genetics of von Willebrand disease. Haematol Rep. 2005;1: 3–8.Google Scholar
  86. 86.
    Pruss CM, Golder M, Bryant A, Hegadorn CA, Burnett E, Laverty K, et al. Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models. Blood. 2011;117(16):4358–66.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev. 2010;24(3):123–34.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Mannucci PM. Treatment of von Willebrand’s Disease. N Engl J Med. 2004;351(7):683–94.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest. 1986;77(3):947.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Shen M-C, Chen M, Ma G-C, Chang S-P, Lin C-Y, Lin B-D, et al. De novo mutation and somatic mosaicism of gene mutation in type 2A, 2B and 2M VWD. Thromb J. 2016;14(1):36.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Fressinaud E, Mazurier C, Meyer D. Molecular genetics of type 2 von Willebrand disease. Int J Hematol. 2002;75(1):9–18.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Ahmad F, Jan R, Kannan M, Obser T, Hassan MI, Oyen F, et al. Characterisation of mutations and molecular studies of type 2 von Willebrand disease. Thromb Haemost. 2013;109(1):39–46.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Hillery CA, Mancuso DJ, Sadler JE, Ponder JW, Jozwiak MA, Christopherson PA, et al. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin-but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood. 1998;91(5):1572–81.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Ginsburg D, Bowie E. Molecular genetics of von Willebrand disease. Blood. 1992;79(10):2507–19.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Mannucci PM. How I treat patients with von Willebrand disease. Blood. 2001;97(7):1915–9.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Rodeghiero F, Castaman G, Tosetto A. How I treat von Willebrand disease. Blood. 2009;114(6):1158–65.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood. 2004;103(6):2032–8.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Castaman G, Goodeve A, Eikenboom J. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013;98(5):667–74.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Amesse LS, Pfaff-Amesse T, Leonardi R, Uddin D, French JA. Oral contraceptives and DDAVP nasal spray: patterns of use in managing vWD-associated menorrhagia: a single-institution study. J Pediatr Hematol/Oncol. 2005;27(7):357–63.CrossRefGoogle Scholar
  100. 100.
    Curnow J, Pasalic L, Favaloro EJ. Treatment of von Willebrand disease. Semin Thromb Hemost. 2016 Mar;42(2):133–46.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Thompson AR, Gill JC, Ewenstein B, Mueller-Velten G, Schwartz B. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P®). Haemophilia. 2004;10(1):42–51.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Federici A, Barillari G, Zanon E, Mazzucconi M, Musso R, Targhetta R, et al. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand’s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia. 2010;16(1):101–10.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Lethagen S, Kyrle P, Castaman G, Haertel S, Mannucci P. von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost. 2007;5(7):1420–30.Google Scholar
  104. 104.
    Gill JC, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek FW, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038–46.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Schinco P, Dorina C, Valeri F, Borchiellini A, Teruzzi C, Mantuano M. Long-Term Prophylaxis in Patients with Von Willebrand Disease and Recurrent Bleeding in Italy. Blood. 2014;124(21):50–6.Google Scholar
  106. 106.
    Mannucci P, Franchini M. Laboratory monitoring of replacement therapy for major surgery in von Willebrand disease. Haemophilia. 2017;23:182–7.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    James A, Konkle B, Kouides P, Ragni M, Thames B, Gupta S, et al. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia. 2015;21(1):81–7.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Simionescu AA, Buinoiu NF, Berbec N. Von Willebrand disease type 2 in pregnancy−a critical clinical association. Transfus Apher Sci. 2017;56:269–71.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Akbar Dorgalaleh
    • 1
  • Shadi Tabibian
    • 1
  • Yavar Shiravand
    • 1
  • Emmanuel J. Favaloro
    • 2
    • 3
  1. 1.Department of Hematology and Blood TransfusionSchool of Allied Medicine, Iran University of Medical SciencesTehranIran
  2. 2.Haematology, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead HospitalWestmeadAustralia
  3. 3.Sydney Centres for Thrombosis and HaemostasisWestmeadAustralia

Personalised recommendations